drugset
drugset / Trial / NCT03575078

ARQ761 + PARP Inhibitor in Refractory Solid Tumors

NCT03575078 ↗

Phase 1 Withdrawn University of Texas Southwestern Medical Center
NaSingle-groupOpen-labelTreatment

Summary

Open Label, dose escalation in a 3+3 study design to establish the RP2D of the combination of ARQ761 and a PARP inhibitor, Olaparib

Timeline

Start
2018-06-25
Primary completion
2019-05-15
Completion
2019-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject ARQ761 Small molecule — —
Background Olaparib Small molecule — Oral

Indications

lymphoma